refametinib

Small moleculeexperimental

Clinical trial activity

13 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2007 (NCT00610194)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1
Mol. weight
572.34 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bay869766
  • bay 869766
  • bay-869766
  • bay-86-9766
  • bay-86-9766
  • bay86-9766
  • n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
  • rdea119
  • rdea119
  • rdea119
  • rdea 119
  • rdea-119
  • rdea-119
  • rdea-119
  • refametinib
  • refametinib
  • refametinib
  • refametinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05754736Phase 2Dec 1, 2022Shandong first medical University
NCT02346032Phase 2Jun 30, 2015Sungkyunkwan University
NCT02168777Phase 1Jun 1, 2014Bayer
NCT01915602Phase 2Sep 27, 2013Bayer
NCT01915589Phase 2Sep 16, 2013Bayer
NCT01925638Phase 1Sep 1, 2013Bayer
NCT01764828Phase 1Feb 1, 2013Bayer
NCT01392521Phase 1Jul 1, 2011Bayer
NCT01251640Phase 1/Phase 2 (Phase 2)Jan 1, 2011Bayer
NCT01204177Phase 2Dec 1, 2010Bayer
NCT01179295Phase 1Nov 19, 2010Bayer
NCT00785226Phase 1/Phase 2 (Phase 2)Nov 1, 2008Bayer
NCT00610194Phase 1Nov 1, 2007Bayer
Showing 13 of 13 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BayerFor profit111122007
Shandong first medical UniversityAcademic/Hospital1112022
Sungkyunkwan UniversityAcademic/Hospital1112015
3 organizations
Page 1 / 1